ABBVIE
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- Conditions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 50
- Registration Number
- NCT05411211
- Locations
- 🇨🇳
The Children's Hospital of Chongqing Medical University /ID# 232114, Chongqing, Chongqing, China
🇨🇳Wuhan Children's Hospital /ID# 242274, Wuhan, Hubei, China
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT05407636
- Locations
- 🇺🇸
Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
🇺🇸Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸Hamilton Glaucoma Center Shiley Eye Center UCSD, La Jolla, California, United States
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
- Conditions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 111
- Registration Number
- NCT05394792
- Locations
- 🇨🇦
Dermatology Research Institute - Blackfoot Trail /ID# 246344, Calgary, Alberta, Canada
🇨🇦Rejuvenation Dermatology - Edmonton Downtown /ID# 246298, Edmonton, Alberta, Canada
🇨🇦Lynde Institute for Dermatology /ID# 246341, Markham, Ontario, Canada
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
- Conditions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 156
- Registration Number
- NCT05394805
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University /ID# 243386, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University /ID# 242804, Chengdu, Sichuan, China
🇨🇳Zhejiang Provincial Hospital of Chinese Medicine /ID# 243443, Hangzhou, Zhejiang, China
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 6
- Registration Number
- NCT05376839
- Locations
- 🇺🇸
Clinical Pharmacology of Miami /ID# 246573, Miami, Florida, United States
🇺🇸Orlando Clinical Research Ctr /ID# 246052, Orlando, Florida, United States
🇺🇸TX Liver Inst, Americ Res Corp /ID# 246572, San Antonio, Texas, United States
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05368558
- Locations
- 🇯🇵
Hayakawa Clinic /ID# 242432, Kure City, Hiroshima, Japan
🇯🇵National Hospital Organization Kure Medical Center /ID# 243405, Kure-shi, Hiroshima, Japan
🇯🇵Hokkaido University Hospital /ID# 243245, Sapporo-shi, Hokkaido, Japan
Expanded Access to Bimatoprost (Durysta)
- Conditions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05338606
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
- Conditions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 93
- Registration Number
- NCT05327920
- Locations
- 🇭🇺
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 234201, Gyor, Gyor-Moson-Sopron, Hungary
🇭🇺Debreceni Egyetem-Klinikai Kozpont /ID# 246156, Debrecen, Hajdu-Bihar, Hungary
🇭🇺Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 234204, Budapest, Hungary
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT05316220
- Locations
- 🇺🇸
Angel Kids Pediatrics /ID# 244874, Jacksonville, Florida, United States
🇺🇸UH Cleveland Medical Center /ID# 243375, Cleveland, Ohio, United States
🇺🇸Treken Primary Care /ID# 241302, Atlanta, Georgia, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
- Conditions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05317494
- Locations
- 🇬🇷
University General Hospital Attikon /ID# 248265, Athens, Attiki, Greece
🇬🇷Olympion General Clinic /ID# 268392, Patras, Achaia, Greece
🇬🇷General Hospital of Athens Gennimatas /ID# 245968, Athens, Attiki, Greece